



N8 Centre for Translational Regenerative Medicine

RegeNer8, in collaboration with the Centre for Prospective Regulation, University of York present:

The regulatory framework for regenerative medicine: challenges and opportunities

Friday 25th April 2008, 9.30 am – 4.00 pm, Hilton, York

Spaces are limited, to avoid disappointment please [click here](#) to register now!

Speakers include:

Keynote: Dr Christopher Bravery, Pharmaceutical Assessor, MHRA

Christopher Bravery is a pharmaceutical assessor in the biologicals and biotechnology unit within the licensing division of the MHRA. His role encompasses undertaking quality assessment of new biological medicines, as well as variations to existing licenses, the majority being via the centralised procedure administered by the EMEA. Further duties at the MHRA include assessment of clinical trials applications and providing scientific advice.

Christopher also undertakes scientific advice for the EMEA, and is a member of their cell products working party. He has over 8 years R&D experience in biotech, including creation of transgenic pigs for xenotransplantation at Imutran Ltd (owned by Novartis) and a range of cell therapy products at Intercytex Ltd.



Dr Alison Wilson - Principal Consultant, CellData Services

Alison provides specialist regulatory affairs advice for tissue and cell products. She has previously held roles as regulatory affairs manager for Smith & Nephew Wound Management, and has 18 years experience of regulatory affairs in medicinal products and medical devices. Her experience includes: registration of medical devices, medicinal products and human tissue products, including the applicability of medicinal product registration requirements to tissue products. She also has experience in the registration of

human tissue products in US, Canada, Australia, South Africa and Japan, as well as close working links with EUCOMED Human Tissues Task Force.

Alison was nominated as the UK expert for ISO (International Standards Organisation) TC150/WG 11 - Tissue Engineered Medical Products, and she also advises a wide range of organisations such as the MHRA, the BIA and the ABHI.

Other speakers include:

- Prof Andrew Webster, Centre for Prospective Regulation, University of York and Director of the ESRC Stem Cell Initiative
- Prof Sheila MacNeil, Centre for Biomaterials and Tissue Engineering, University of Sheffield
- Dr Sushma Jassal, Intercytex

Who should attend this event:

- Clinicians and healthcare managers involved in commercializing regenerative therapies
- Healthcare and biotech industry leaders developing R&D tools and commercializing regenerative therapies
- Universities, research organizations and others with regenerative medicine advances or technologies to transfer
- Venture capitalists, advisors and business development executives looking for investment opportunities and the creation of new partnerships
- Anyone who wants to find out more about current regulations and legislation regarding regenerative medicine

For further details including the full programme, please click [here](#)

For sponsorship and exhibition information please contact gaia.hassan@celsatlifecell.com or visit www.regener8.ac.uk.



**Moving Forward:
The Northern Way**



THE UNIVERSITY *of York*